Multicenter clinical trial on functional evaluation of transoral laser microsurgery for supraglottic laryngeal carcinomas
Laryngo-Rhino-Otologie · 01.02.2025 · 104 (02) · 94-102
DOI: 10.1055/a-2321-5968 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.02.2025. Verfasst von Petra Ambrosch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, and Christian-Albrechts-Univers…. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Microsurgery, Laser Therapy, Laryngectomy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Transoral laser microsurgery (TLM) is an accepted and effective treatment strategy for supraglottic carcinomas. Data on oncologic and to a lesser extent functional outcomes have been published by mainly European specialized single institutions. TLM for supraglottic carcinomas has never been tested in a multicenter trial on its applicability as surgical standard at every hospital.
Objectives
To test the efficacy of TLM supraglottic laryngectomy (TLM-SGL) in terms of swallowing function, oncologic outcome parameters, morbidity, complications of treatment, and quality of life in a multicenter setting.
Methods
The study is designed as a multicenter (approximately 25 centers), non-randomized, single-arm study with a targeted number of 200 previously untreated patients with squamous cell carcinomas (SCC) of the supraglottic larynx T2/T3 N0–3 M0; UICC stage II–IVa. The surgical treatment consists of TLM-SGL and elective or therapeutic uni- or bilateral selective neck dissection (SND). After pathologic risk stratification adjuvant radio- (RT) or radiochemotherapy (RCT) is indicated. Patients are followed-up for 2 years post surgically. Swallowing function is assessed by fibreoptic endoscopic evaluation of swallowing (FEES). The primary endpoint is aspiration-free swallowing at 12 months as established using FEES and defined as grade < 6 of penetration-aspiration scale (PAS). Secondary endpoints include local control, larynx preservation, overall and disease-free survival, complications and side effects of treatment, prevalence of tracheostomy and percutaneous endoscopic gastrostomy (PEG)-tube-feeding, and dysphagia-specific quality of life (QoL) assessed by the MD Anderson Dysphagia Inventory (MDADI) as well as voice-related QoL assessed by the Voice Handicap Index (VHI).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, and Christian-Albrechts-University Kiel, Kiel, Germany.
- Clinic of Otorhinolaryngology, University of Leipzig, Leipzig, Germany.
- Department of Radiation Oncology, University of Erlangen-Nuremberg, Erlangen, Germany.
- Clinical Trial Unit, UMG, University of Göttingen, Göttingen, Germany.
- Institute of Medical Informatics and Statistics, Christian-Albrechts-University Kiel, Germany.
Zitieren
APA
Ambrosch, P., Fazel, A., Dietz, A., Fietkau, R., Tostmann, R., & Borzikowsky, C. (2025). Multicenter clinical trial on functional evaluation of transoral laser microsurgery for supraglottic laryngeal carcinomas. Laryngo-Rhino-Otologie, 104(02), 94-102. https://doi.org/10.1055/a-2321-5968
Vancouver
Ambrosch P, Fazel A, Dietz A, Fietkau R, Tostmann R, Borzikowsky C. Multicenter clinical trial on functional evaluation of transoral laser microsurgery for supraglottic laryngeal carcinomas. Laryngo-Rhino-Otologie. 2025;104(02):94-102. doi:10.1055/a-2321-5968
BibTeX
@article{Ambrosch2025,
author = {Ambrosch, Petra and Fazel, Asita and Dietz, Andreas and Fietkau, Rainer and Tostmann, Ralf and Borzikowsky, Christoph},
title = {Multicenter clinical trial on functional evaluation of transoral laser microsurgery for supraglottic laryngeal carcinomas},
journal = {Laryngo-Rhino-Otologie},
year = {2025},
volume = {104},
number = {02},
pages = {94--102},
doi = {10.1055/a-2321-5968}
}
EUVIMED